BioCentury | Jul 5, 2017
Clinical News

DSMC recommends continuation of Biotron's Phase II trial of BIT225 for HIV-1 infection

...quarter. BIT225 is a small molecule inhibitor of HCV p7 protein and HIV Vpu protein. Biotron Ltd....
...and safety; immune activation and pharmacokinetics Status: Phase II ongoing Milestone: Phase II data (3Q17) Alicia Parker BIT225 Biotron Ltd. HCV...
BioCentury | Mar 24, 2014
Clinical News

BIT225: Additional Phase II data

...ribavirin for a total of 48 weeks and received antiretroviral therapy (ART) throughout the trial. Biotron...
...Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron peginterferon alfa-2b and Rebetol ribavirin. Biotron Ltd....
BioCentury | Dec 9, 2013
Clinical News

BIT225: Interim Phase II data

...peginterferon alfa-2b and ribavirin for 28 days achieved undetectable HCV RNA levels at week 12. Biotron...
...the American Association for the Study of Liver Diseases meeting in Washington, D.C. This year, Biotron...
...Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron peginterferon alfa-2b and Rebetol ribavirin. Biotron Ltd....
BioCentury | Sep 2, 2013
Clinical News

BIT225: Completed Phase II enrollment

...In July, Biotron completed enrollment of 12 treatment-naïve patients co-infected with HIV and HCV genotype 1...
...antiretroviral therapy (ART) for HIV infection and will continue ART in the trial. Next month, Biotron...
...to treat HCV infection. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon and Copegus ribavirin. Biotron Ltd....
BioCentury | Mar 25, 2013
Clinical News

BIT225: Preliminary Phase Ib/IIa data

...1 infection and a Phase II trial to treat patients co-infected with HIV and HCV. Biotron Ltd....
BioCentury | Dec 10, 2012
Clinical News

BIT225: Phase II started

...1, 2 or 3. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon and Copegus ribavirin. Biotron Ltd....
BioCentury | Jan 9, 2012
Clinical News

BIT225: Additional Phase IIa data

...SOC alone for 44 weeks. Data were presented at the HEP DART meeting in Koloa. Biotron...
...HCV RNA levels vs. placebo plus SOC at day 35 (see BioCentury, Oct. 17. 2011). Biotron...
...Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron peginterferon alfa-2b and Rebetol ribavirin. Biotron Ltd....
BioCentury | Oct 17, 2011
Finance

Highlights of weekly biotech stock moves

...56% and 44% for placebo plus SOC in a Phase IIb trial (see B14) . Biotron Ltd....
BioCentury | Oct 17, 2011
Clinical News

BIT225: Preliminary Phase IIa data

...levels compared to placebo plus SOC. Data for low-dose BIT225 plus SOC were not disclosed. Biotron...
...Phase III testing. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon alfa-2a and Copegus ribavirin. Biotron Ltd....
BioCentury | Mar 21, 2011
Clinical News

BIT225: Phase II ongoing

...trial has already enrolled 12 patients. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys and Copegus. Biotron Ltd....
Items per page:
1 - 10 of 12
BioCentury | Jul 5, 2017
Clinical News

DSMC recommends continuation of Biotron's Phase II trial of BIT225 for HIV-1 infection

...quarter. BIT225 is a small molecule inhibitor of HCV p7 protein and HIV Vpu protein. Biotron Ltd....
...and safety; immune activation and pharmacokinetics Status: Phase II ongoing Milestone: Phase II data (3Q17) Alicia Parker BIT225 Biotron Ltd. HCV...
BioCentury | Mar 24, 2014
Clinical News

BIT225: Additional Phase II data

...ribavirin for a total of 48 weeks and received antiretroviral therapy (ART) throughout the trial. Biotron...
...Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron peginterferon alfa-2b and Rebetol ribavirin. Biotron Ltd....
BioCentury | Dec 9, 2013
Clinical News

BIT225: Interim Phase II data

...peginterferon alfa-2b and ribavirin for 28 days achieved undetectable HCV RNA levels at week 12. Biotron...
...the American Association for the Study of Liver Diseases meeting in Washington, D.C. This year, Biotron...
...Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron peginterferon alfa-2b and Rebetol ribavirin. Biotron Ltd....
BioCentury | Sep 2, 2013
Clinical News

BIT225: Completed Phase II enrollment

...In July, Biotron completed enrollment of 12 treatment-naïve patients co-infected with HIV and HCV genotype 1...
...antiretroviral therapy (ART) for HIV infection and will continue ART in the trial. Next month, Biotron...
...to treat HCV infection. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon and Copegus ribavirin. Biotron Ltd....
BioCentury | Mar 25, 2013
Clinical News

BIT225: Preliminary Phase Ib/IIa data

...1 infection and a Phase II trial to treat patients co-infected with HIV and HCV. Biotron Ltd....
BioCentury | Dec 10, 2012
Clinical News

BIT225: Phase II started

...1, 2 or 3. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon and Copegus ribavirin. Biotron Ltd....
BioCentury | Jan 9, 2012
Clinical News

BIT225: Additional Phase IIa data

...SOC alone for 44 weeks. Data were presented at the HEP DART meeting in Koloa. Biotron...
...HCV RNA levels vs. placebo plus SOC at day 35 (see BioCentury, Oct. 17. 2011). Biotron...
...Merck & Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.) markets PegIntron peginterferon alfa-2b and Rebetol ribavirin. Biotron Ltd....
BioCentury | Oct 17, 2011
Finance

Highlights of weekly biotech stock moves

...56% and 44% for placebo plus SOC in a Phase IIb trial (see B14) . Biotron Ltd....
BioCentury | Oct 17, 2011
Clinical News

BIT225: Preliminary Phase IIa data

...levels compared to placebo plus SOC. Data for low-dose BIT225 plus SOC were not disclosed. Biotron...
...Phase III testing. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys peginterferon alfa-2a and Copegus ribavirin. Biotron Ltd....
BioCentury | Mar 21, 2011
Clinical News

BIT225: Phase II ongoing

...trial has already enrolled 12 patients. Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland) markets Pegasys and Copegus. Biotron Ltd....
Items per page:
1 - 10 of 12